You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer
|
|---|---|
| Published in |
BMC Cancer, October 2015
|
| DOI | 10.1186/s12885-015-1672-4 |
| Pubmed ID | |
| Authors |
Chris E. Adkins, Mohamed I. Nounou, Tanvirul Hye, Afroz S. Mohammad, Tori Terrell-Hall, Neel K. Mohan, Michael A. Eldon, Ute Hoch, Paul R. Lockman |
| Abstract |
Brain metastases are an increasing problem in women with invasive breast cancer. Strategies designed to treat brain metastases of breast cancer, particularly chemotherapeutics such as irinotecan, demonstrate limited efficacy. Conventional irinotecan distributes poorly to brain metastases; therefore, NKTR-102, a PEGylated irinotecan conjugate should enhance irinotecan and its active metabolite SN38 exposure in brain metastases leading to brain tumor cytotoxicity. Female nude mice were intracranially or intracardially implanted with human brain seeking breast cancer cells (MDA-MB-231Br) and dosed with irinotecan or NKTR-102 to determine plasma and tumor pharmacokinetics of irinotecan and SN38. Tumor burden and survival were evaluated in mice treated with vehicle, irinotecan (50 mg/kg), or NKTR-102 low and high doses (10 mg/kg, 50 mg/kg respectively). NKTR-102 penetrates the blood-tumor barrier and distributes to brain metastases. NKTR-102 increased and prolonged SN38 exposure (>20 ng/g for 168 h) versus conventional irinotecan (>1 ng/g for 4 h). Treatment with NKTR-102 extended survival time (from 35 days to 74 days) and increased overall survival for NKTR-102 low dose (30 % mice) and NKTR-102 high dose (50 % mice). Tumor burden decreased (37 % with 10 mg/kg NKTR-102 and 96 % with 50 mg/kg) and lesion sizes decreased (33 % with 10 mg/kg NKTR-102 and 83 % with 50 mg/kg NKTR-102) compared to conventional irinotecan treated animals. Elevated and prolonged tumor SN38 exposure after NKTR-102 administration appears responsible for increased survival in this model of breast cancer brain metastasis. Further, SN38 concentrations observed in this study are clinically achieved with 145 mg/m(2) NKTR-102, such as those used in the BEACON trial, underlining translational relevance of these results. |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 49 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 20% |
| Researcher | 9 | 18% |
| Student > Master | 6 | 12% |
| Other | 5 | 10% |
| Student > Postgraduate | 4 | 8% |
| Other | 8 | 16% |
| Unknown | 8 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 20% |
| Chemistry | 7 | 14% |
| Agricultural and Biological Sciences | 7 | 14% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Other | 2 | 4% |
| Unknown | 8 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 October 2015.
All research outputs
#4,180,223
of 22,830,751 outputs
Outputs from BMC Cancer
#1,000
of 8,305 outputs
Outputs of similar age
#56,389
of 279,229 outputs
Outputs of similar age from BMC Cancer
#29
of 234 outputs
Altmetric has tracked 22,830,751 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,305 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,229 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 234 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.